Literatur
Pace J, Paladugu P, Das B, He JC, Mallipattu SK (2019) Targeting STAT3 signaling in kidney disease. Am J Physiol Renal Physiol 316(6):F1151–F1161
Patera F, Cudzich-Madry A, Huang Z, Fragiadaki M (2019) Renal expression of JAK2 is high in polycystic kidney disease and its inhibition reduces cystogenesis. Sci Rep 9(1):4491
Testa F, Magistroni R (2019) ADPKD current management and ongoing trials. J Nephrol. https://doi.org/10.1007/s40620-019-00679-y
Torres VE, Higashihara E, Devuyst O, Chapman AB, Gansevoort RT, Grantham JJ, Perrone RD, Ouyang J, Blais JD, Czerwiec FS (2016) Effect of tolvaptan in autosomal dominant polycystic kidney disease by CKD stage: results from the TEMPO 3:4 trial. Clin J Am Soc Nephrol 11(5):803–811
Weimbs T, Talbot JJ (2013) STAT3 signaling in polycystic kidney disease. Drug Discov Today Dis Mech 10(3/4):e113–e118
Wilson PD (2004) Polycystic kidney disease. N Engl J Med 350(2):151–164
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
H. Kübber und S. Dolff geben an, dass kein Interessenkonflikt besteht.
Additional information
Redaktion
O. Witzke, Essen
Rights and permissions
About this article
Cite this article
Kübber, H., Dolff, S. JAK-STAT-Signalweg in der Pathogenese der autosomal-dominanten polyzystischen Nierenerkrankung (ADPKD). Nephrologe 15, 188–190 (2020). https://doi.org/10.1007/s11560-020-00427-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11560-020-00427-5